Zetia May Help Protect Arteries in Patients with Type 2 Diabetes

Zetia May Help Protect Arteries in Patients with Type 2 Diabetes What is Type 2 Diabetes? This is a chronic and life-long disease in which there is high level of glucose (sugar) in the blood. A common form of diabetes in which your muscle cells, liver, and fat do not respond correctly to insulin. It is also known as insulin resistance.

Symptoms of Type 2 Diabetes- The common symptoms of this form of Diabetes are:     

Fatigue Blurred vision Increased thirst Frequent urination Hunger

Infection in kidney, skin and bladder

How Zetia can Help Protect Arteries in Type 2 Data analysis has found that the cholesterol-lowering medication ezetimibe, (Zetia) may have had a part in ensuring type 2 Diabetes in a few people, creating cardiovascular infections.

The study, called the Stop Atherosclerosis in Native Diabetics Study (or SANDS), enlisted 427 Native Americans, age 40 and over, with type 2 diabetes. The members had no history of cardiovascular ailments however they had atherosclerosis, or the development of greasy plaque in the veins that is connected to cardiovascular illness.

They were separated into two treatment groups: Members of the standard treatment group planned to bring down their LDL cholesterol levels to 100 mg/dl or less, and reduce their systolic pulse (the top number) to 130 mmHg or less, while those in the escalated treatment group went for LDL cholesterol levels of 70 mg/dl or less, and systolic circulatory strain levels of 115 mmHg or less.

The primary cholesterol treatment used by the escalated group was statin drugs; however in the event that these medications did not reduce LDL cholesterol levels enough, ezetimibe was included. Of the 223 individuals in the serious treatment group, 154 wound up taking statins alone, and 69 took statins in addition to ezetimibe.

Throughout the three year study period, members had their carotid course intima-media thickness (CIMT) measured by ultrasound. This test demonstrated whether atherosclerosis was increasing or diminishing. It was found to have expanded, or

deteriorated, in the standard treatment group and diminished, or enhanced, to a comparable degree in both arms of the serious treatment group. The analysts presumed that forcefully bringing down LDL cholesterol levels with statins alone, or with statins in addition to ezetimibe if necessary, seems to present a comparative advantage in protecting individuals with type 2 diabetes from atherosclerosis. At the end of the day, ezetimibe could assume a part in decreasing cardiovascular danger in individuals for whom statins alone do not reduce cholesterol levels.

These discoveries appear differently in relation to the consequences of the ENHANCE trial, which was expounded on not long ago in the online journal section, "Vytorin Study Results Disappoint." That study found that treatment with the statin drug simvastatin (Zocor) in addition to ezetimibe, (sold together as the blend drug Vytorin) did not moderate the development of plaque in the carotid supply route any more than treatment with simvastatin alone.

There are some critical differences between the two studies. The ENHANCE study, with 720 members, was larger than the SANDS study. It was a twofold visually impaired study, implying that members and their specialists did not know which drugs they were taking, while SANDS was an open-mark study. In any case, numerous members in ENHANCE had taken cholesterol reducing medications before the start of the study, which may have affected the results, while SANDS members had received no other treatments. Another distinction was that SANDS centered around individuals with type 2 diabetes, while ENHANCE did not.

Please follow us on Facebook, Linkedin and Twitter